Core Viewpoint - Protagonist Therapeutics, Inc. has received FDA approval for its drug ICOTYDE™, which is expected to significantly enhance its product portfolio and financial outlook [2][3]. Group 1: Product Development - ICOTYDE™ is the first and only oral peptide targeting the IL-23 receptor, designed for treating moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older [2]. - The approval was based on four phase 3 studies involving 2,500 patients, all of which met their primary endpoints and demonstrated a favorable safety profile [2]. Group 2: Financial Implications - The company will receive a $50 million milestone payment upon FDA approval and is eligible for royalties ranging from 6% to 10% on sales [3]. - Protagonist Therapeutics has the potential to earn up to $580 million in future milestone payments, which will further strengthen its financial position [3]. Group 3: Market Performance - Despite the positive news regarding FDA approval, PTGX's stock price has slightly decreased by 0.14%, currently priced at $97.09 [4]. - The stock has experienced volatility, with a trading range between a low of $90.58 and a high of $99.44 on the day of reporting [4]. - Over the past year, PTGX has reached a high of $99.45 and a low of $39.60, with a market capitalization of approximately $6.2 billion [4].

FDA approval of ICOTYDEâ"¢ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide Accessibility StatementSkip Navigation Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic tre ...